Our performance

PDF

Since October 2006, the UHCT Alliance has been implementing the following domestic or multi-national clinical trials.
summary as of March 2013

Item Details Counts
Total   67
Type of study Multi-national 38
　Asian 3
Domestic 29
Cooperation of operability study of trail # No. of Cooperation of operability study of trail for execution plan 9
Cooperation for selection of hospitals $ No. of selection of hospitals by ours 41
Days for selection of hospitals - without giving out paper, report for client and holiday 4-8
Briefing session for collaborate protocol % No. of trial / No. of approved by IRB 37 / 47 &
Status of the implementation Under review by IRB 8
Approved by IRB 2
Entry completed 45
Abort 5
Pending（Pre-IRB stage) 1
No establishment 5
The other 1
Meeting of improvement progress Times / trials 17 / 42
Requirements to hold a meeting
1)within 3 months from a clinicaltrial agreemeent
2)enrolled patients under 30% ofcontracted number of patients		 March, September, December,2008 and monthly in principlesince then for projects meetingthe requirements
  • # As an optional case
  • $ Implementation after clients and our office have consulted
  • % Project staff manage progress of the trail after meeting of protocol.
  • & There are 6 cases without briefing session, since each study is assisted by only one establishment.

 

 

Executing rate of completed entry for clinical trial until March 2013

No. Serial No. Indication Type of trial
Who		 Who did select hospitals Hospital for project briefing session No of Participating hospitals Months for entry Total agreements Total implementations Executing rate
1 A#1 Parkinson('s) disease Domestic Client Tokyo Jan-07 5 12 60 54 90.0%
2 A#3 Autosomal dominant polycystic kidney disease Global Client Chiba Feb-07 3 16 23 22 95.7%
3 A#6 Hepatitis B Domestic Client Tokyo Feb-07 3 20 20 18 90.0%
4 A#7 Multiple sclerosis Domestic Client TMD# Aug-07 5 24 18 13 72.2%
5 A#8 Philadelphia chromosome-positive chronicmyeloid leukemia Global Alliance Tokyo Aug-07 6 12 21 19 90.5%
6 A#9 Diabetic peripheral neuropathic pain Domestic Alliance Niigata Sep-07 2 14 11 8 72.7%
7 A#10 Prostatic cancer Domestic Client Tokyo Aug-07 6 12 29 19 65.5%
8 A#13 Postherpetic neuralgia Domestic Client+Alliance Tokyo jun-07 5 16 15 8 53.3%
9 A#14 Chronic noncancerous pain Domestic Client+Alliance Tokyo jun-07 5 8 29 24 82.8%
10 A#15 Overactive bladder Asian(4 Nationals) Alliance Shinshu - 1 6 9 9 100％
11 A#16 Rheumatoid arthritis Domestic Alliance TMD# Nov-07 3 7 22 14 63.6%
12 A#17 Hepatocellular carcinoma Global Client Chiba Oct-07 2 14 18 13 72.2%
13 A#18 Rheumatoid arthritis Domestic Alliance TMD# Nov-07 3 13 16 14 87.5%
14 A#19 Prostatic cancer with bone metastasis Global Client Tokyo Dec-07 4 14 8 5 62.5%
15 A#20 Prostatic cancer without bone metastasis Global Client Tokyo Dec-07 4 28 9 7 77.8%
16 A#21 Multiple sclerosis Domestic Client Tokyo Feb-08 3 21 5 4 80.0%
17 A#23 Alzheimer('s) disease Global Alliance Tokyo Sep-08 2 23 10 10 100%
18 A#24 Acute pulmonary thromboembolism Domestic Alliance Tokyo jun-08 4 3 5 2 40.0%
19 A#25 Acute deep vein thrombosis Domestic Alliance Tokyo jun-08 4 12 13 9 69.2%
20 A#26 Chronic obstructive pulmonary disease Asian(7 Nationals) Alliance Gunma Sep-08 2 9 6 4 66.7%
21 A#27 MRSA infection Domestic Alliance Niigata Oct-08 3 13 13 7 53.8%
22 A#28 Chronic obstructive pulmonary disease Global Alliance Chiba Sep-08 2 12 14 10 71.4%
23 A#29 Influenza virus infections in high-risk patients Domestic Alliance Niigata - 1 6 3 2 66.7%
24 A#31 Chronic heart failure with high plasma BNP Global Alliance Chiba May-09 4 27 17 11 64.7%
25 A#32 Pulmonary arterial hypertension Global Alliance Tokyo - 2 36 4 4 100.0%
26 A#33 Pulmonary arterial hypertension Global Alliance Tokyo - 2 39 4 4 100.0%
27 A#34 Initial craniotomy Domestic Alliance Niigata Apr-09 2 12 27 27 100%
28 A#35 Chronic thromboembolic pulmonary hypertension Global Alliance Tokyo Nov-08 2 37 6 5 83%
29 A#36 Chronic thromboembolic pulmonary hypertension Global Alliance Tokyo Nov-08 2 41 4 4 100%
30 A#37 Chronic lymphocytic leukemia Domestic Alliance Chiba May-09 3 16 3 2 66.7%
31 A#38 Non-small-cell lung cancer Global Alliance Tokyo Apr-09 4 5 11 8 72.7%
32 A#39 Parkinson('s) disease Domestic Client Chiba jun-09 5 16 48 35 72.9%
33 A#40 Parkinson('s) disease Domestic Client Chiba jun-09 5 25 31 26 83.9%
34 A#42 cryptosporidiosis in children Domestic Alliance - - 1 20 1 1 100.0%
35 A#44 Chronic obstructive pulmonary disease Global Alliance Tokyo Sep-10 4 9 13 8 61.5%
36 A#45 Diabetic macular edema Domestic Alliance Shinshu - 4 14 23 19 82.6%
37 A#46 Parkinson('s) disease Domestic Alliance Tsukuba Jan-11 5 22 21 15 71.4%
38 A#47 Essential thrombocythemia Domestic Alliance Chiba - 2 8 6 6 100.0%
39 A#49 Psoriasis Global Client Gunma Dec-10 2 9 8 8 100.0%
40 A#50 Polycythemia vera Global Alliance - - 1 6 2 2 100.0%
41 A#53 Acute symptomatic deep vein thrombosis Domestic Alliance Gunma - 3 14 14 10 71.4%
42 A#54 Acute symptomatic pulmonary embolism Domestic Alliance Gunma - 5 13 11 10 90.9%
43 A#55 hormone-insensitive prostate cancer Domestic Client Tokyo Nov-11 3 10 6 5 83.3%
44 A#57 Essential thrombocythemia Domestic Alliance Chiba - 2 7 6 6 100.0%
45 A#60 General anesthesia Domestic Client Tokyo Oct-12 5 4 44 33 75.0%
Total　 687 544 79.2%

# Tokyo Medical and Dental University, University hospital of Medicine